Abstract
Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
